-+ 0.00%
-+ 0.00%
-+ 0.00%

Earnings Update: Journey Medical Corporation (NASDAQ:DERM) Just Reported And Analysts Are Trimming Their Forecasts

Simply Wall St·11/15/2026 14:53:59
Listen to the news

As you might know, Journey Medical Corporation (NASDAQ:DERM) last week released its latest quarterly, and things did not turn out so great for shareholders. Revenues missed expectations somewhat, coming in at US$19m, but statutory earnings fell catastrophically short, with a loss of US$0.05 some 150% larger than what the analysts had predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

earnings-and-revenue-growth
NasdaqCM:DERM Earnings and Revenue Growth November 15th 2026

Taking into account the latest results, the current consensus from Journey Medical's three analysts is for revenues of US$100.7m in 2027. This would reflect a huge 45% increase on its revenue over the past 12 months. Journey Medical is also expected to turn profitable, with statutory earnings of US$0.40 per share. In the lead-up to this report, the analysts had been modelling revenues of US$116.3m and earnings per share (EPS) of US$0.44 in 2027. It looks like sentiment has declined substantially in the aftermath of these results, with a substantial drop in revenue estimates and a real cut to earnings per share numbers as well.

See our latest analysis for Journey Medical

The analysts made no major changes to their price target of US$13.33, suggesting the downgrades are not expected to have a long-term impact on Journey Medical's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Journey Medical analyst has a price target of US$14.00 per share, while the most pessimistic values it at US$13.00. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Journey Medical is an easy business to forecast or the the analysts are all using similar assumptions.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Journey Medical's past performance and to peers in the same industry. For example, we noticed that Journey Medical's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 35% growth to the end of 2027 on an annualised basis. That is well above its historical decline of 2.5% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 8.6% annually. So it looks like Journey Medical is expected to grow faster than its competitors, at least for a while.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Journey Medical. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. The consensus price target held steady at US$13.33, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Journey Medical. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Journey Medical going out to 2028, and you can see them free on our platform here..

It might also be worth considering whether Journey Medical's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.